Bivariate analysis | Multivariate analysis | |||||||
---|---|---|---|---|---|---|---|---|
OR | (95% CI) | p | OR | (95% CI) | p | |||
Female vs male | 0,814 | 0,336 | 1974 | 0,650 | ||||
Caucasian vs Non-Caucasian | 1883 | 0,304 | 11,684 | 0,497 | ||||
Baseline age (per yrs) | 0,989 | 0,956 | 1023 | 0,524 | ||||
BMI ≤18 vs > 18 | 1133 | 0,335 | 3840 | 0,841 | ||||
TDF as part of first ARV regimen vs TDF as part of second or further ARV regimens | 0,341 | 0,162 | 0,715 | 0,004 | 1040 | 0,195 | 5537 | 0,963 |
Previous therapy duration (per yrs) | 1057 | 0,988 | 1131 | 0,110 | 0,948 | 0,854 | 1051 | 0,309 |
Baseline CD4 cell count (per cells/mL) | 1000 | 0,999 | 1001 | 0,907 | ||||
Baseline Plasma HIV-RNA level (per log cps/mL) | 0,793 | 0,677 | 0,929 | 0,004 | 0,809 | 0,578 | 1132 | 0,216 |
HCV coinfection | 1444 | 0,505 | 4131 | 0,493 | ||||
Baseline creatinine (per mg/dL) | 1999 | 0,138 | 28,861 | 0,611 | ||||
Duration of treatment with TDF (per months) | 1006 | 0,998 | 1015 | 0,162 | 0,998 | 0,987 | 1009 | 0,672 |
Use of protease inhibitors | 0,823 | 0,396 | 1712 | 0,602 | ||||
Hypertension | 2039 | 0,769 | 5405 | 0,152 | 0,991 | 0,318 | 3084 | 0,987 |
Diabetes | 2477 | 0,714 | 8595 | 0,153 | 3670 | 0,914 | 14,740 | 0,067 |
Bone diseasea | 3178 | 1529 | 6603 | 0,002 | 3147 | 1361 | 7279 | 0,007 |
ABCC2–24 C > T (CC vs CT/TT) | 0,689 | 0,332 | 1428 | 0,316 | ||||
ABCC4 3463 A > G (GG vs AG/AA) | 4667 | 1247 | 17,464 | 0,022 | 2663 | 0,610 | 11,621 | 0,193 |
ABCC10 rs2125739 T > C (CC vs TC/TT) | 0,530 | 0,111 | 2525 | 0,425 |